Verzenio Is Significant– Cuts The Risk of Cancer Coming Back In Some Women With Early Breast Cancer– A First For CDK4/6 Inhibitors

Published Jun 25, 2020

Verzenio Is Significant– Cuts The Risk of Cancer Coming Back In Some Women With Early Breast Cancer– A First For CDK4/6 Inhibitors

During a clinical trial, researchers found that CDK4/CDK6 inhibitor Verzenio may have a huge impact on women battling early stage breast cancer by decreasing the likelihood of the cancer returning.

NOW
PLAYING
Fox News Reporter Jennifer Griffin, 51, Beat Triple-Negative Breast Cancer; Know The Treatment Options
NOW
PLAYING
5 Popular Breast Cancer Myths Debunked
NOW
PLAYING
CDK4/6 Inhibitors for Breast Cancer Explained
NOW
PLAYING
Hormonal Therapies For Breast Cancer Are Safe to Use During the COVID-19 Pandemic
NOW
PLAYING
HER2-Positive Metastatic Breast Cancer Treatment Options
NOW
PLAYING
Treatment Options for Metastatic Triple Negative Breast Cancer

Treatment: Lymphedema

SEE MORE   

Treatment: Lymphedema

Lymphedema is a chronic swelling that can occur after breast cancer surgery and radiation.

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.